CSCIF — COSCIENS Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $6.56m
- $1.40m
- $7.50m
Annual cashflow statement for COSCIENS Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.37 | -22.7 | -3.48 | -15.3 | -10.4 |
| Depreciation | |||||
| Non-Cash Items | -1.25 | 7.48 | -0.693 | 0.905 | 0.405 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.895 | 1.44 | 0.153 | -1.77 | 0.292 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -8.58 | -13.7 | -2.58 | -14.6 | -8.47 |
| Capital Expenditures | -0.639 | -0.011 | -0.722 | -1.16 | -0.706 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.019 | -0.001 | -0.008 | 26.2 | 0.252 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.658 | -0.012 | -0.73 | 25.1 | -0.454 |
| Financing Cash Flow Items | -3.12 | 0.016 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 51 | -0.118 | -0.357 | -0.588 | -0.407 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 41 | -14.7 | -3.51 | 9.71 | -9.09 |